Skip to main content
Premium Trial:

Request an Annual Quote

Downloads & Upgrades: Wisconsin Package, CHARMm, Modeler, Delphi, SeqFold, PathwayPrism


San Diego-based Accelrys has released five of its top-selling software products on IBM eServer pSeries systems running AIX, the first product releases stemming from the recently announced global strategic alliance between the two companies.

Accelrys’ Wisconsin Package, CHARMm, Modeler, Delphi, and SeqFold applications are now available for the IBM platform and the companies said they would port “the majority” of Accelrys’ life sciences software to IBM systems over the next three quarters of 2002.


Physiome Sciences of Princeton, NJ, released version 2.0 of its PathwayPrism biological simulation technology platform at BioSilico 2002 in New York last week. PathwayPrism 2.0 is an enterprise version of the original platform, and allows users to distribute and exchange simulation data across all geographic and therapeutic boundaries, said Peter Brooks, vice president of product development and operations.

Filed under

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.